Related Experiment Video
Updated: Mar 25, 2026

Author Spotlight: Induction of Experimental Endotoxemic Shock in Pigs for Studying Hemodynamic and Respiratory Failure
Published on: December 8, 2023
Integration of Polymyxin-B Hemoadsorption Device into a CRRT Circuit for Endotoxic Septic Shock in a Child: A Case
Giovanni Ceschia1, Germana Longo1, Jose M Igeno San Miguel1
1Pediatric Nephrology Unit, Department of Woman's and Child's Health, University-Hospital of Padova, 35128 Padova, Italy.
Abstract:
Introduction: Endotoxin-mediated septic shock is a life-threatening condition characterized by systemic inflammation and hemodynamic instability. While Polymyxin-B hemoadsorption (Toraymyxin®) is well-studied in adults, its use in pediatric patients remains less explored and requires modified approaches to minimize invasiveness and complications. Case Presentation: We report a 9-year-old boy (25 kg) with endotoxin-mediated septic shock due to Klebsiella pneumoniae, who developed oliguric acute kidney injury requiring continuous renal replacement therapy (CRRT). On Day 4, worsening conditions prompted the initiation of Toraymyxin® treatment, directly integrated into the ongoing CRRT circuit. This approach minimized extracorporeal volume expansion, avoided circuit replacement, and was complication-free. The patient improved rapidly, allowing CRRT discontinuation and transfer to the ward within 28 days. Conclusions: This case highlights the feasibility, safety, and potential benefits of integrating the Toraymyxin® cartridge into an ongoing CRRT circuit in pediatric septic shock, minimizing extracorporeal volume, avoiding additional vascular access, and supporting hemodynamic stabilization.
Related Concept Videos
Continuous Renal Replacement Therapy
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Pharmacokinetics in Pediatric Patients: Drug Excretion
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Acute Kidney Injury V: Interprofessional Care
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

